

Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2020 and Host Conference Call on September 29, 2020

London and Redwood City, Calif., September 15, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announces that it will release interim financial results for the six months ended June 30, 2020 on Tuesday, September 29, 2020 at 7:00 a.m. EDT / 12:00 p.m. BST. Following the release of the financial results, Mereo's management team will host a conference call beginning at 8:00 a.m. EDT / 1:00 p.m. BST on Tuesday, September 29, 2020 to discuss the results and provide a general corporate update.

Conference Call Details

Date: Tuesday, September 29, 2020

Time: 8:00 a.m. EDT / 1:00 p.m. BST

Dial-in numbers: (866) 688-2942 (U.S.) or +1 (561) 569-9224 (U.K./International)

Conference ID number: 9572439

A live and archived webcast may be accessed by visiting the Investors sections of the Company's website at <https://www.mereobiopharma.com/investors/results-reports-and-presentations/>. The archived webcast will remain available on the Company's website following the live call.

About Mereo BioPharma

[Mereo BioPharma](#) is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab ("Anti-TIGIT"), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta ("OI"), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency ("AATD") and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.

Mereo BioPharma Contacts:

Mereo

Denise Scots-Knight, Chief Executive Officer

+44 (0)333 023 7300

N+1 Singer (Nominated Adviser and Broker to Mereo)

Phil Davies

Will Goode

+44 (0)20 7496 3081

Burns McClellan (US Investor Relations Adviser to Mereo)

Lisa Burns

Steve Klass

+01 212 213 0006

FTI Consulting (UK Public Relations Adviser to Mereo)

Simon Conway

Ciara Martin

+44 (0)20 3727 1000

Investors

investors@mereobiopharma.com

